PMID- 19375467
OWN - NLM
STAT- MEDLINE
DCOM- 20091009
LR  - 20090811
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 70
IP  - 8
DP  - 2009 Aug
TI  - Human leukocyte antigen antibody detection and kidney allocation within 
      Eurotransplant.
PG  - 636-9
LID - 10.1016/j.humimm.2009.04.010 [doi]
AB  - The human leukocyte antigen (HLA) antibody status of a patient on the waiting 
      list is one of the parameters for the allocation of donor kidneys within 
      Eurotransplant. The introduction of more sensitive solid phase assays in addition 
      to the current gold standard, complement-dependent cytotoxicity, will have an 
      obvious impact on the allocation provided that the results have the same value. 
      However, in contrast to a positive complement-dependent cytotoxicity crossmatch 
      because of donor HLA-specific antibodies, which is considered a contraindication 
      for transplantation, antibodies detected in the solid phase are a risk factor 
      rather than a contraindication. Furthermore, the higher sensitivity of 
      Luminex-based screening assays, especially, will lead to a significantly higher 
      number of highly sensitized patients and may affect the exclusivity of the 
      acceptable mismatch program, which was initiated to give priority to highly 
      sensitized patients. More data on the clinical relevance of antibodies detected 
      by solid phase assays are necessary before their relevance for organ allocation 
      can be established.
FAU - Claas, Frans H J
AU  - Claas FH
AD  - Eurotransplant Reference Laboratory, Leiden University Medical Center, Department 
      of Immunohaematology and Blood Transfusion, Leiden, the Netherlands. 
      fhjclaas@lumc.nl
FAU - Doxiadis, Iiias I N
AU  - Doxiadis II
LA  - eng
PT  - Journal Article
DEP - 20090416
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
RN  - 9007-36-7 (Complement System Proteins)
SB  - IM
MH  - Complement System Proteins/immunology
MH  - Cytotoxicity Tests, Immunologic
MH  - Europe
MH  - Flow Cytometry
MH  - Graft Rejection/blood/*diagnosis/*immunology/prevention & control
MH  - HLA Antigens/*immunology
MH  - *Histocompatibility
MH  - Humans
MH  - Immunization
MH  - Immunosorbent Techniques
MH  - Isoantibodies/blood/*immunology
MH  - *Kidney Transplantation
MH  - Microspheres
MH  - Monitoring, Physiologic
MH  - Practice Guidelines as Topic
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - *Tissue and Organ Procurement
EDAT- 2009/04/21 09:00
MHDA- 2009/10/10 06:00
CRDT- 2009/04/21 09:00
PHST- 2009/03/06 00:00 [received]
PHST- 2009/04/09 00:00 [accepted]
PHST- 2009/04/21 09:00 [entrez]
PHST- 2009/04/21 09:00 [pubmed]
PHST- 2009/10/10 06:00 [medline]
AID - S0198-8859(09)00099-8 [pii]
AID - 10.1016/j.humimm.2009.04.010 [doi]
PST - ppublish
SO  - Hum Immunol. 2009 Aug;70(8):636-9. doi: 10.1016/j.humimm.2009.04.010. Epub 2009 
      Apr 16.